Oral glutathione (300 mg daily for four months) led to notable decreases in ALT, suggesting reduced liver inflammation
References Alba M, Fintini D, Sagazio A, et al
Studies have shown that DSIP can pass the blood brain barrier (BBB) in rats, mice, dogs, and humans, making it a potential option for targeting neurological disorders, aforementioned mood disorders, and sleep disorders [11]
Moderate- and high-intensity exercise seems to lead to more GLP-1 in the body, while its unclear if light exercise does the same
[1] After review, the FDA concluded that there is no clinical need to add semaglutide, tirzepatide, or liraglutide to the bulks list